Giredestrant plus Everolimus in Advanced Breast Cancer.
An all-oral drug combination delayed cancer progression longer than standard treatment in some advanced breast cancer patients.
This randomized controlled trial examined Giredestrant plus Everolimus in Advanced Breast Cancer. The PubMed abstract reports An all-oral giredestrant-everolimus regimen led to significantly longer progression-free survival than standard endocrine therapy-everolimus among patients with ER-positive, HER2-negative advanced breast cancer who had received a CDK4/6 inhibitor previously, m.
What the study was
- Study design
- Randomized controlled trial
- Population
- Human participants or patients described in the abstract
- Sample size
- 373
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- The New England journal of medicine
Why it surfaced
Randomized controlled trial with human evidence; score reflects novelty, clinical relevance, design quality, and population or unmet-need value under the v1.3 rubric.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.